Yasamin Ostadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasamin Ostadi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Javad Khanali
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publications - Babak Sabet
Department of General Surgery, School of Medicine, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Behrang Kazeminezhad
Department of Pathology, Clinical Research Development Center, Shahid Modarres Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran 1983535511, Iran
2 shared publications - Fatemeh A. Tehrani
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Feizollah Niazi
Department of Plastic and Reconstructive Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Hassan Niknejad
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The synergistic regenerative and anti-inflammatory effects of Ponesimod and amniotic epithelial stem cells in the Cuprizone animal model of multiple sclerosis
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe synergistic regenerative and anti-inflammatory effects of Ponesimod and amniotic epithelial stem cells in the Cuprizone animal model of multiple sclerosis
- Open Access
- 3 August 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1279-1302
Injectable extracellular matrix microparticles for regenerative and biocompatible soft tissue augmentation
Decellularized extracellular matrices (DEMs) have been widely investigated as promising biomaterials for soft tissue augmentation. In contrast, the use of decellularized human amniotic membrane (dHAM) represents a novel approach within this field, offering unique potential for clinical application. The objective of this study is to develop an “off-the-shelf” bioactive soft tissue filler from crosslinked and non-crosslinked dHAM in the injectable microparticle formulation. We used physical and enzymatic processes for decellularization and milling for fabricating the injectable matrix. The decellularization, crosslinking and detoxification protocol removed immunogenic cellular components, preserved collagen and glycosaminoglycan content, and reduced residual crosslinker to sub-cytotoxic levels. Consequently, both crosslinked and non-crosslinked powder extractions promoted cell viability and proliferation and did not affect cell migration in culture. Moreover, the crosslinked powder showed higher stability upon in vitro enzymatic degradation and prolonged volume retention in the subcutaneous guinea pig model. Histopathologic evaluation of the implants showed that immune cell infiltration markedly resolved over the 12-week study period. Moreover, immunohistochemistry staining for CD68 and CD163 macrophage markers indicated the abundance of CD163-positive cells, commonly associated with an anti-inflammatory or M2-like phenotype. Staining for CD31 endothelial cell marker demonstrated the formation of blood vessels with intraluminal RBCs and endothelial cell lining within the implants, which is indicative of neovascularization. Therefore, dHAM demonstrated long-term volume retention, reduced immune cell infiltration, and was associated with a CD163-positive macrophage phenotype and evidence of vascularization in the animal model. This study suggests dHAM as a readily deliverable biomaterial and a promising candidate to address clinical translational needs for soft tissue reconstruction.
- 3 August 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1279-1302
Open AccessInjectable extracellular matrix microparticles for regenerative and biocompatible soft tissue augmentation
Decellularized extracellular matrices (DEMs) have been widely investigated as promising biomaterials for soft tissue augmentation. In contrast, the use of decellularized human amniotic membrane (dHAM) represents a novel approach within this field, offering unique potential for clinical application. The objective of this study is to develop an “off-the-shelf” bioactive soft tissue filler from crosslinked and non-crosslinked dHAM in the injectable microparticle formulation. We used physical and enzymatic processes for decellularization and milling for fabricating the injectable matrix. The decellularization, crosslinking and detoxification protocol removed immunogenic cellular components, preserved collagen and glycosaminoglycan content, and reduced residual crosslinker to sub-cytotoxic levels. Consequently, both crosslinked and non-crosslinked powder extractions promoted cell viability and proliferation and did not affect cell migration in culture. Moreover, the crosslinked powder showed higher stability upon in vitro enzymatic degradation and prolonged volume retention in the subcutaneous guinea pig model. Histopathologic evaluation of the implants showed that immune cell infiltration markedly resolved over the 12-week study period. Moreover, immunohistochemistry staining for CD68 and CD163 macrophage markers indicated the abundance of CD163-positive cells, commonly associated with an anti-inflammatory or M2-like phenotype. Staining for CD31 endothelial cell marker demonstrated the formation of blood vessels with intraluminal RBCs and endothelial cell lining within the implants, which is indicative of neovascularization. Therefore, dHAM demonstrated long-term volume retention, reduced immune cell infiltration, and was associated with a CD163-positive macrophage phenotype and evidence of vascularization in the animal model. This study suggests dHAM as a readily deliverable biomaterial and a promising candidate to address clinical translational needs for soft tissue reconstruction.
- Open Access
- 27 November 2025
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 3 (1) , e22
Evaluation of Suicide Risk Among Patients With Tramadol Toxicity: A Cross-Sectional Study in an Emergency Department
Background: Tramadol misuse and poisoning are serious health concerns in regions with limited prescription regulation, including Iran. Beyond its toxicologic effects, the pharmacologic properties of tramadol and associated psychosocial factors may contribute to elevated suicide risk. Accordingly, this study aimed to assess suicide risk using the SAD PERSONS scale among patients presenting with acute tramadol poisoning to the emergency department. Methods: This descriptive cross-sectional study evaluated 80 patients with confirmed tramadol poisoning presenting to Sina Hospital during 2021–2022. Demographic data, motives for tramadol use, adverse effects, and SAD PERSONS scores were collected, and suicide risk was categorized as low (0–4), moderate (5–6), or high (7–10). The obtained data were analyzed using descriptive and inferential statistical tests. Results: The mean age of participants was 36.25±6.81 years. Overall, 66.25% and 61.25% were male and single, respectively. The average daily tramadol dose was 912.96±245.16 mg. The mean SAD PERSONS score was 6.85±2.37, with 43.75%, 28.75%, and 27.5% categorized as high, moderate, and low risk, respectively. Moreover, pleasure-seeking (40%), depressive symptoms (33.75%), and sexual performance enhancement (27.5%) were the most frequently cited motives for use. Eventually, dizziness (60%), nausea (55%), and seizures (31.25%) were the most commonly reported adverse effects. Conclusion: A substantial proportion of tramadol-poisoned patients demonstrated moderate-to-high suicide risk, highlighting tramadol poisoning as a toxicologic emergency and a psychiatric crisis. Integrating structured suicide screening and timely psychiatric evaluation into emergency care is essential for early detection and prevention of recurrent self-harm.
- 27 November 2025
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 3 (1) , e22
Open AccessEvaluation of Suicide Risk Among Patients With Tramadol Toxicity: A Cross-Sectional Study in an Emergency Department
Background: Tramadol misuse and poisoning are serious health concerns in regions with limited prescription regulation, including Iran. Beyond its toxicologic effects, the pharmacologic properties of tramadol and associated psychosocial factors may contribute to elevated suicide risk. Accordingly, this study aimed to assess suicide risk using the SAD PERSONS scale among patients presenting with acute tramadol poisoning to the emergency department. Methods: This descriptive cross-sectional study evaluated 80 patients with confirmed tramadol poisoning presenting to Sina Hospital during 2021–2022. Demographic data, motives for tramadol use, adverse effects, and SAD PERSONS scores were collected, and suicide risk was categorized as low (0–4), moderate (5–6), or high (7–10). The obtained data were analyzed using descriptive and inferential statistical tests. Results: The mean age of participants was 36.25±6.81 years. Overall, 66.25% and 61.25% were male and single, respectively. The average daily tramadol dose was 912.96±245.16 mg. The mean SAD PERSONS score was 6.85±2.37, with 43.75%, 28.75%, and 27.5% categorized as high, moderate, and low risk, respectively. Moreover, pleasure-seeking (40%), depressive symptoms (33.75%), and sexual performance enhancement (27.5%) were the most frequently cited motives for use. Eventually, dizziness (60%), nausea (55%), and seizures (31.25%) were the most commonly reported adverse effects. Conclusion: A substantial proportion of tramadol-poisoned patients demonstrated moderate-to-high suicide risk, highlighting tramadol poisoning as a toxicologic emergency and a psychiatric crisis. Integrating structured suicide screening and timely psychiatric evaluation into emergency care is essential for early detection and prevention of recurrent self-harm.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0071
Decellularized Extracellular Matrix Scaffolds for Soft Tissue Augmentation: From Host–Scaffold Interactions to Bottlenecks in Clinical Translation
Along with a paradigm shift in looking at soft tissue fillers from space-filling to bioactive materials, decellularized extracellular matrix (DEM) fillers have gained more attention considering their superior bioactivity. However, the complex mechanisms that govern the interaction between host tissues and DEMs have been partially understood. This review first covers the mechanisms that determine immunogenicity, angiogenesis and vasculogenesis, and recellularization and remodeling after DEM implantation into host tissue, with a particular focus on related findings from filler materials. Accordingly, the review delves into the dual role of macrophages and their M1/M2 polarization paradigm to form both constructive and destructive immune responses to DEM implants. Moreover, the contribution of macrophages in angiogenesis has been elucidated, which includes but is not limited to the secretion of angiogenic growth factors and extracellular matrix (ECM) remodeling. The findings challenge the traditional view of immune cells as solely destructive entities in biomaterials and indicate their multifaceted roles in tissue regeneration. Furthermore, the review discusses how the compositional factors of DEMs, such as the presence of growth factors and matrikines, can influence angiogenesis, cell fate, and differentiation during the recellularization process. It is also shown that the biomechanical properties of DEMs, including tissue stiffness, modulate cell responses through mechanotransduction pathways, and the structural properties of DEMs, such as scaffold porosity, impact cell–cell and cell–ECM interactions. Finally, we pointed out the current clinical applications, the bottlenecks in the clinical translation of DEM biomaterials into soft tissue fillers, as well as the naïve research areas of the field.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0071
Decellularized Extracellular Matrix Scaffolds for Soft Tissue Augmentation: From Host–Scaffold Interactions to Bottlenecks in Clinical Translation
Along with a paradigm shift in looking at soft tissue fillers from space-filling to bioactive materials, decellularized extracellular matrix (DEM) fillers have gained more attention considering their superior bioactivity. However, the complex mechanisms that govern the interaction between host tissues and DEMs have been partially understood. This review first covers the mechanisms that determine immunogenicity, angiogenesis and vasculogenesis, and recellularization and remodeling after DEM implantation into host tissue, with a particular focus on related findings from filler materials. Accordingly, the review delves into the dual role of macrophages and their M1/M2 polarization paradigm to form both constructive and destructive immune responses to DEM implants. Moreover, the contribution of macrophages in angiogenesis has been elucidated, which includes but is not limited to the secretion of angiogenic growth factors and extracellular matrix (ECM) remodeling. The findings challenge the traditional view of immune cells as solely destructive entities in biomaterials and indicate their multifaceted roles in tissue regeneration. Furthermore, the review discusses how the compositional factors of DEMs, such as the presence of growth factors and matrikines, can influence angiogenesis, cell fate, and differentiation during the recellularization process. It is also shown that the biomechanical properties of DEMs, including tissue stiffness, modulate cell responses through mechanotransduction pathways, and the structural properties of DEMs, such as scaffold porosity, impact cell–cell and cell–ECM interactions. Finally, we pointed out the current clinical applications, the bottlenecks in the clinical translation of DEM biomaterials into soft tissue fillers, as well as the naïve research areas of the field.